OPTIMIZATION OF REHABILITATION OF PARESIS IN CRITICAL CONDITIONS
Keywords:
immune attack, paralysis, polyneuromyopathy, sepsis, neuromuscular blockade, rehabilitationAbstract
Guillain-Barre (gee-YAH-buh-RAY) syndrome is a condition in which the body's immune system attacks the nerves. It can cause weakness, numbness or paralysis. Weakness and tingling in the hands and feet are usually the first symptoms. These sensations can quickly spread and may lead to paralysis. In its most serious form, Guillain-Barre syndrome is a medical emergency. Most people with the condition need treatment in a hospital. Guillain-Barre syndrome is rare, and the exact cause is not known. But two-thirds of people have symptoms of an infection in the six weeks before Guillain-Barre symptoms begin. Infections can include a respiratory or a gastrointestinal infection, including COVID-19. Guillain-Barre also can be caused by the Zika virus. There's no known cure for Guillain-Barre syndrome. Several treatment options can ease symptoms and help speed recovery. Most people recover completely from Guillain-Barre syndrome, but some serious illnesses can be fatal. While recovery may take up to several years, most people are able to walk again six months after symptoms first began. Some people may have lasting effects, such as weakness, numbness or fatigue.
References
Aladawi M., Elfil M., Abu-Esheh B., et al. (2021). Guillain–Barré syndrome as a complication of COVID‑19: A systematic review. Canadian Journal of Neurological Sciences.
Alonso-Zaldivar M., Rodríguez Y., et al. (2023). Incidence of Guillain‑Barré syndrome worldwide between 1985–2020: A systematic review. Global Epidemiology.
Alrawili O. N., Alharbi A. I., et al. (2023). Pathophysiology, etiology, causes, and treatment of Guillain–Barré syndrome. International Journal of Community Medicine and Public Health.
Chowdhury S., Chowdhury S., Islam M. (2023). Association of Guillain–Barré syndrome following COVID‑19 vaccination. Human Vaccines & Immunotherapeutics.
Gorson K. C. (2025). Evolving understanding of Guillain‑Barré syndrome pathophysiology and the central role of the classical complement pathway in axonal injury. Frontiers in Neurology.
Hadhiah A., Elbaih A., et al. (2024). Guillain–Barré syndrome post‑SARS‑CoV‑2 vaccine: a systematic review and data analysis. Frontiers in Neurology.
Maatoug R., Mezghani N., et al. (2023). Guillain–Barré syndrome in 220 patients with COVID‑19: clinical features and outcomes. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.
Marcus R., Derman P. (2023). What Is Guillain–Barré Syndrome? JAMA.
Oshomoji O. I., Aransiola T. B., et al. (2024). Autoimmune mechanisms in Guillain‑Barré syndrome subtypes: A systematic review. Bulletin of Faculty of Physical Therapy.
Priyadarshini B., Anuhya V., Mahapatra A. (2025). Clinico-epidemiological profile and prediction of outcome in children with Guillain‑Barre syndrome. Italian Journal of Pediatrics.
van Doorn P. A., Hadden R. D. M., Cornblath D. R. (2025). Guillain–Barré syndrome: a comprehensive review. PubMed Central.
Weiss N., Simard J. M., Ziai W. (2025). Critical insights for intensivists on Guillain‑Barré syndrome. Annals of Intensive Care.
Widinayake L., Rajapaksha D., Nair N. (2024). Guillain–Barré syndrome of AMAN type associated with herpes zoster: a case report. BMC Neurology.
Wijdicks E. F. M., Rajabally Y. A. (2024). Current treatment practice of Guillain‑Barré syndrome. Neurology.
Wijdicks E. F. M., Rajabally Y. A., Hughes R. A. C. (2024). Efficacy of IVIG for the axonal variants of Guillain–Barré syndrome: A systematic review and meta‑analysis. Neurology.






Azerbaijan
Türkiye
Uzbekistan
Kazakhstan
Turkmenistan
Kyrgyzstan
Republic of Korea
Japan
India
United States of America
Kosovo